Results 11 to 20 of about 125,371 (166)
Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity
Veterinary Dermatology, Volume 34, Issue 6, Page 532-542, December 2023., 2023 Background – Hymenoptera envenomation occurs frequently in people and dogs and can trigger anaphylaxis. Venom immunotherapy (VIT) is the only preventative treatment for Hymenoptera hypersensitivity and is indicated for people with severe adverse reactions to insect stings. Rush VIT is an accelerated VIT induction schedule performed in people.
Alexandra Moore +4 more
wiley +1 more source
The safety of rush immunotherapy in the management of canine atopic dermatitis—230 cases
Veterinary Dermatology, Volume 34, Issue 5, Page 385-392, October 2023., 2023 Background – The duration of the induction phase of allergen‐specific immunotherapy conventionally is a period of several weeks, during which the volume of an allergen solution, administered by injection, is gradually increased until the maintenance dose is reached.
Tamara Weitzer, Ralf Mueller
wiley +1 more source
Veterinary Dermatology, Volume 34, Issue 4, Page 348-354, August 2023., 2023 Background – Glycerinated allergen extracts contain 50% glycerin, an excellent preservative. While glycerin is a recognised irritant in humans, the utility of glycerinated extracts for intradermal testing has not been validated in dogs. Hypothesis/Objective – To determine and compare the effects of glycerin on immediate cutaneous reactions to ...
Frane Banovic, Cheryl Vargo, Tara Denley
wiley +1 more source
Veterinary Dermatology, Volume 34, Issue 2, Page 91-98, April 2023., 2023 Background – Atopic dermatitis (AD) is one of the most common skin diseases in small animal practice. Allergen immunotherapy (AIT) is the only curative treatment for the disease, and oral, subcutaneous and intralymphatic administration of allergens are commonly employed.
Ralf S. Mueller +9 more
wiley +1 more source
Veterinary Dermatology, Volume 33, Issue 6, Page 553-558, December 2022., 2022 Background – Canine flank alopecia (CFA) is characterized by seasonally recurring noninflammatory, occasionally hyperpigmented alopecia predominantly in the thoracolumbar area. Previous studies suggest that reduced production of endogenous melatonin may play a role in the pathogenesis of this condition, and placebo‐controlled studies on the efficacy of
Millie U. M. Y. Verschuuren +4 more
wiley +1 more source
The Journal of Latin American and Caribbean Anthropology, Volume 27, Issue 1-2, Page 37-56, June 2022., 2022 Resumen La reventa de gasolina brasilera en la frontera Venezuela–Brasil es un acontecimiento emergente que facilita el entendimiento sociopolítico nuevo de las estrategias de sobrevivencia locales más allá de la resiliencia social e informalidad en tiempos de crisis.
Morelia Morillo Ramos, Eva van Roekel
wiley +1 more source
Diversity and Distributions, Volume 28, Issue 1, Page 4-24, January 2022., 2022 Abstract Aim Holm oak (Quercus ilex L.) is regarded as a keystone plant species. Trophic interactions may affect the distribution and abundance of phytophagous species, but the number of arthropod species that use holm oak as a food resource and their levels of host specificity are not yet known.
Juan Antonio Hernández‐Agüero +3 more
wiley +1 more source
Onset and duration of action of lokivetmab in a canine model of IL‐31 induced pruritus
Veterinary Dermatology, Volume 32, Issue 6, Page 681-e182, December 2021., 2021 Onset of antipruritic action of lokivetmab in dogs. Laboratory‐bred beagle dogs were dosed subcutaneously with either placebo or lokivetmab at 2.0 mg/kg on Day (D) 0. Approximately 2.5 h post‐dosing, pruritus was induced using canine interleukin (IL)‐31. Animals were observed for pruritic behaviours for a total of 2 h (3–5 h post‐treatment with placebo
Timothy J. Fleck +6 more
wiley +1 more source
Veterinary Dermatology, Volume 32, Issue 5, Page 477-e131, October 2021., 2021 Background – Interleukin (IL)‐31 is an important mediator in canine atopic dermatitis (cAD) and also may be dysregulated in other allergic diseases. Hypothesis/Objectives – To demonstrate the efficacy and safety of lokivetmab (canine anti‐IL‐31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs.
Leen Van Brussel +4 more
wiley +1 more source
Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability
Developmental Medicine &Child Neurology, Volume 63, Issue 8, Page 991-997, August 2021., 2021 Aim To evaluate the effect of repeated onabotulinum neurotoxin A injections for the treatment of drooling in children with neurodisabilities. Method This was a retrospective cohort study, in which the first, second, and third onabotulinum neurotoxin A injection were compared within children treated between 2000 and 2020.
Stijn Bekkers +5 more
wiley +1 more source